These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35127966)

  • 1. Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2.
    Scott TA; Supramaniam A; Idris A; Cardoso AA; Shrivastava S; Kelly G; Grepo NA; Soemardy C; Ray RM; McMillan NAJ; Morris KV
    Mol Ther Methods Clin Dev; 2022 Mar; 24():355-366. PubMed ID: 35127966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tagged extracellular vesicles with the RBD of the viral spike protein for delivery of antiviral agents against SARS-COV-2 infection.
    Fu Y; Xiong S
    J Control Release; 2021 Jul; 335():584-595. PubMed ID: 34089793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
    Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK
    mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles.
    Wu C; Xu Q; Wang H; Tu B; Zeng J; Zhao P; Shi M; Qiu H; Huang Y
    Acta Pharm Sin B; 2022 Mar; 12(3):1523-1533. PubMed ID: 34522576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain.
    Ma H; Zeng W; Meng X; Huang X; Yang Y; Zhao D; Zhou P; Wang X; Zhao C; Sun Y; Wang P; Ou H; Hu X; Xiang Y; Jin T
    J Virol; 2021 Apr; 95(10):. PubMed ID: 33658349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering Extracellular Vesicles Enriched with Palmitoylated ACE2 as COVID-19 Therapy.
    Xie F; Su P; Pan T; Zhou X; Li H; Huang H; Wang A; Wang F; Huang J; Yan H; Zeng L; Zhang L; Zhou F
    Adv Mater; 2021 Dec; 33(49):e2103471. PubMed ID: 34665481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
    Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
    J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters.
    Aksu M; Kumar P; Güttler T; Taxer W; Gregor K; Mußil B; Rymarenko O; Stegmann KM; Dickmanns A; Gerber S; Reineking W; Schulz C; Henneck T; Mohamed A; Pohlmann G; Ramazanoglu M; Mese K; Groß U; Ben-Yedidia T; Ovadia O; Fischer DW; Kamensky M; Reichman A; Baumgärtner W; von Köckritz-Blickwede M; Dobbelstein M; Görlich D
    Antiviral Res; 2024 Jan; 221():105778. PubMed ID: 38065245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency.
    Mariotti S; Capocefalo A; Chiantore MV; Iacobino A; Teloni R; De Angelis ML; Gallinaro A; Pirillo MF; Borghi M; Canitano A; Michelini Z; Baggieri M; Marchi A; Bucci P; McKay PF; Acchioni C; Sandini S; Sgarbanti M; Tosini F; Di Virgilio A; Venturi G; Marino F; Esposito V; Di Bonito P; Magurano F; Cara A; Negri D; Nisini R
    Front Immunol; 2021; 12():750386. PubMed ID: 34764961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein.
    Van Ert HA; Bohan DW; Rogers K; Fili M; Rojas Chávez RA; Qing E; Han C; Dempewolf S; Hu G; Schwery N; Sevcik K; Ruggio N; Boyt D; Pentella MA; Gallagher T; Jackson JB; Merrill AE; Knudson CM; Brown GD; Maury W; Haim H
    Microbiol Spectr; 2022 Feb; 10(1):e0267621. PubMed ID: 35080430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
    Qiao B; Olvera de la Cruz M
    ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.
    Tai W; He L; Zhang X; Pu J; Voronin D; Jiang S; Zhou Y; Du L
    Cell Mol Immunol; 2020 Jun; 17(6):613-620. PubMed ID: 32203189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2.
    Larue RC; Xing E; Kenney AD; Zhang Y; Tuazon JA; Li J; Yount JS; Li PK; Sharma A
    Bioconjug Chem; 2021 Jan; 32(1):215-223. PubMed ID: 33356169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Hybrid Soluble gp130/Spike-Nanobody Fusion Protein Simultaneously Blocks Interleukin-6
    Ettich J; Werner J; Weitz HT; Mueller E; Schwarzer R; Lang PA; Scheller J; Moll JM
    J Virol; 2022 Feb; 96(4):e0162221. PubMed ID: 34935434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding.
    Yang J; Lin S; Sun H; Chen Z; Yang F; Lin X; Guo L; Wang L; Wen A; Zhang X; Dai Y; He B; Cao Y; Dong H; Liu X; Chen B; Li J; Zhao Q; Lu G
    Front Immunol; 2022; 13():820336. PubMed ID: 35663966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracellular vesicles carry SARS-CoV-2 spike protein and serve as decoys for neutralizing antibodies.
    Troyer Z; Alhusaini N; Tabler CO; Sweet T; de Carvalho KIL; Schlatzer DM; Carias L; King CL; Matreyek K; Tilton JC
    J Extracell Vesicles; 2021 Jun; 10(8):e12112. PubMed ID: 34188786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-guided design of a trivalent nanobody cluster targeting SARS-CoV-2 spike protein.
    Jiang X; Qin Q; Zhu H; Qian J; Huang Q
    Int J Biol Macromol; 2024 Jan; 256(Pt 1):128191. PubMed ID: 38000614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Naïve Phage Display Library-Derived Nanobody Neutralizes SARS-CoV-2 and Three Variants of Concern.
    Wu D; Cong J; Wei J; Hu J; Sun W; Ran W; Liao C; Zheng H; Ye L
    Int J Nanomedicine; 2023; 18():5781-5795. PubMed ID: 37869063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
    Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
    EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.